Erratum: Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component (Journal of Cancer Research and Clinical Oncology (2013) 139 (817-827) DOI: 10.1007/s00432-013-1386-4);Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 5, 2013, Pages 817-827

  Park, Inkeun ^a   Cho, Yong Mee ^a   Lee, Jae Lyun ^a   Ahn, Jin Hee ^a   Lee, Dae Ho ^a   Song, Cheryn ^a   Hong, Jun Hyuk ^a   Kim, Choung Soo ^a   Ahn, Hanjong ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Cytoreductive surgery; Percentage of sarcomatoid component; Prognosis; Sarcomatoid renal cell carcinoma; Systemic treatment

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; DENDRITIC CELL VACCINE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; FEMALE; FUNCTIONAL STATUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY CARCINOMA; MALE; METASTASIS POTENTIAL; NEPHRECTOMY; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SARCOMATOID CARCINOMA; TREATMENT RESPONSE;

EID: 84876281881     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1486-1     Document Type: Erratum

References (33)

1. Abel EJ, Culp SH, Matin SF, Tamboli P, Wallace MJ, Jonasch E, Tannir NM, Wood CG (2010) Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol 184:1877-1881
2. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M (2004) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German cooperative renal carcinoma chemoimmunotherapy group (DGCIN). J Clin Oncol 22:1188-1194
3. Bangalore N, Bhargava P, Hawkins MJ (2001) Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature. Ann Oncol 12:271-274
4. Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A (1999) Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 17:523-528
5. Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, Blute ML (2004) Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28:435-441
6. Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY (2011) The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 185:60-66
7. Culine S, Bekradda M, Terrier-Lacombe MJ, Droz JP (1995) Treatment of sarcomatoid renal cell carcinoma: is there a role for chemotherapy? Eur Urol 27:138-141
8. de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, Javidan J, Stricker H, Ro JY, Amin MB (2001) Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 25:275-284
9. Escudier B, Droz JP, Rolland F, Terrier-Lacombe MJ, Gravis G, Beuzeboc P, Chauvet B, Chevreau C, Eymard JC, Lesimple T, Merrouche Y, Oudard S, Priou F, Guillemare C, Gourgou S, Culine S (2002) Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol 168:959-961
10. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655-1659
11. Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI (2009) Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 27:235-241
12. Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J (2012) A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 29:761-767
13. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794-5799
14. Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Moon KC, Ku JH (2007) Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. J Surg Oncol 95:317-323
15. Lee JL, Park I, Park K, Park S, Ahn Y, Ahn JH, Kim TW, Ahn S, Song C, Hong JH, Kim CS, Ahn H (2012) Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. J Cancer Res Clin Oncol 138:687-693
16. Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun A (2003) Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 98:2566-2575
17. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z (2006) 2004 WHO classification of the renal tumors of the adults. Eur Urol 49:798-805
18. Mian BM, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, Pisters LL (2002) Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 167:65-70
19. Michaelson D, McDermott D, Atkins MB, Cho DC, Olivier KM, Schwarzberg AB, Choueiri TK (2010) Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. In: Proceedings of Genitourinary Cancer Symposium, abstr 340
20. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966-970
21. Molina AM, Tickoo SK, Ishill N, Trinos MJ, Schwartz LH, Patil S, Feldman DR, Reuter VE, Russo P, Motzer RJ (2011) Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol 34:454-459
22. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-463
23. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP (2004) Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101:1545-1551
24. Richey SL, Ng C, Lim ZD, Jonasch E, Tannir NM (2011) Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 29:e203-e205
25. Ro JY, Ayala AG, Sella A, Samuels ML, Swanson DA (1987) Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases. Cancer 59:516-526
26. Roubaud G, Gross-Goupil M, Wallerand H, de Clermont H, Dilhuydy MS, Ravaud A (2011) Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma. Oncology 80:214-218
27. Sella A, Logothetis CJ, Ro JY, Swanson DA, Samuels ML (1987) Sarcomatoid renal cell carcinoma. A treatable entity. Cancer 60:1313-1318
28. Shuch B, Said J, La Rochelle JC, Zhou Y, Li G, Klatte T, Kabbinaavar FF, Pantuck AJ, Belldegrun AS (2009) Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology - is up-front resection indicated and, if not, is it avoidable? J Urol 182:2164-2171
29. Shuch B, Said J, LaRochelle JC, Zhou Y, Li G, Klatte T, Pouliot F, Kabbinavar FF, Belldegrun AS, Pantuck AJ (2010) Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer 116:616-624
30. Shuch B, Bratslavsky G, Linehan WM, Srinivasan R (2012) Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist 17:46-54
31. Staehler M, Haseke N, Roosen A, Stadler T, Bader M, Siebels M, Karl A, Stief CG (2010) Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J Med Res 15:287-291
32. Tickoo SK, Alden D, Olgac S, Fine SW, Russo P, Kondagunta GV, Motzer RJ, Reuter VE (2007) Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol 177:1258-1263
33. Wu J, Caliendo G, Hu XP, Dutcher JP (1998) Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma. Med Oncol 15:44-49